- Home
- SPRC
SPRC
SciSparc Ltd.
as 11-15-2024 4:00pm EST
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
| Founded: | 2004 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 793.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.21 - $14.22 | Next Earning Date: | 11-26-2024 |
| Revenue: | $1,747,000 | Revenue Growth: | -47.36% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SciSparc Ltd. News
SPRC Breaking Stock News: Dive into SPRC Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
2 months ago
SciSparc receives FDA approval for trial for Tourette syndrome therapy
GlobeNewswire
2 months ago
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
GlobeNewswire
2 months ago
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
GlobeNewswire
2 months ago
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
MT Newswires
2 months ago
Scisparc Submits FDA Investigational New Drug Application for Tourette Syndrome Treatment
GlobeNewswire
2 months ago
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
MT Newswires
2 months ago
Clearmind Applies for Patent on Anti-Addiction Combination Therapy -- Shares Up After Hours
GlobeNewswire
2 months ago
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
Compare SPRC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRC SciSparc Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.